Celgene Corporation

Managed drug distribution program licensed

Published in Pharma Law Weekly, December 28th, 2004

Celgene Corporation (CELG) announced an agreement providing Barr Pharmaceuticals, Inc., (BRL), Mylan/Bertek (MYL) on behalf of Genpharm, Ranbaxy, and Roche with a non-exclusive license to its patent portfolio directed to methods of safely delivering drugs in potentially high-risk patient populations.

The manufacturers of isotretinoin have licensed these patents with the intention of implementing a new pregnancy risk management system for isotretinoin. The patents are directed to, among other things, Celgene's proprietary S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety) program.

S.T.E.P.S. is the first U.S. Food & Drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry